Drug Type Small molecule drug |
Synonyms NTX 721, NTX721 |
Target |
Mechanism GSK-3β inhibitors(Glycogen synthase kinase-3 beta inhibitors), Sp1 inhibitors(Transcription factor Sp1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization NeuroTau, Inc.Startup |
Active Organization NeuroTau, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Preclinical | US | NeuroTau, Inc.Startup | 19 Dec 2023 |
Brain Injuries, Traumatic | Preclinical | US | NeuroTau, Inc.Startup | 19 Dec 2023 |
Huntington Disease | Preclinical | US | NeuroTau, Inc.Startup | 19 Dec 2023 |
Supranuclear Palsy, Progressive | Preclinical | US | NeuroTau, Inc.Startup | 19 Dec 2023 |